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The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with
folate and vitamin B12 supplementation (FA/VB12) in Japanese patients with solid tumours and to investigate the safety, efficacy, and
pharmacokinetics of pemetrexed. Eligible patients had incurable solid tumours by standard treatments, a performance status 0–2, and
adequate organ function. Pemetrexed from 300 to 1200mgm
 2 was administered as a 10-min infusion on day 1 of a 21-day cycle
with FA/VB12. Totally, 31 patients were treated. Dose-limiting toxicities were alanine aminotransferase (ALT) elevation at
700mgm
 2, and infection and skin rash at 1200mgm
 2. The MTD/RD were determined to be 1200/1000mgm
 2, respectively. The
most common grade 3/4 toxicities were neutropenia (grade (G) 3:29, G4:3%), leucopenia (G3:13, G4:3%), lympopenia (G3:13%) and
ALT elevation (G3:13%). Pemetrexed pharmacokinetics in Japanese were not overtly different from those in western patients. Partial
response was achieved for 5/23 evaluable patients (four with non-small cell lung cancer (NSCLC) and one with thymoma). The
MTD/RD of pemetrexed were determined to be 1200/1000mgm
 2, respectively, that is, a higher RD than without FA/VB12
(500mgm
 2). Pemetrexed with FA/VB12 showed a tolerable toxicity profile and potent antitumour activity against NSCLC in this
study.
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Pemetrexed (LY231514, Alimta
s, Eli Lilly and Company, IN, USA)
is a novel antifolate (Taylor and Patel, 1992) that is approved in the
United States and a number of European Union countries , for
treatment of patients with malignant pleural mesothelioma (MPM)
in combination with cisplatin, and non-small cell lung cancer
(NSCLC) after prior chemotherapy as a single agent. In vitro
experiments show that pemetrexed inhibits three enzymes in folate
metabolism: thymidylate synthase (TS), dihydrofolate reductase
(DHFR), and glycinamide ribonucleotide formyltransferase
(GARFT) (Shih et al, 1998). Given the schedule dependency
observed preclinically, three regimens were explored in phase I
studies: (1) 0.2–5.2mgm
 2 daily for 5 days every 3 weeks
(McDonald et al, 1998); (2) 10–40mgm
 2 weekly for 4 weeks
repeated every 6 weeks (Rinaldi et al, 1995); and (3) 50–
700mgm
 2 every 3 weeks (Rinaldi et al, 1999).
The third regimen (one dose every 3 weeks) was chosen for
subsequent phase II studies because of its convenient administra-
tion, ability to give repeated doses, and occurrence of objective
responses. The original maximum tolerated dose (MTD) and the
recommended dose (RD) was 600mgm
 2, but was decreased to
500mgm
 2 owing to toxicities experienced early in phase II
studies. The initial phase I and II studies showed that myelosup-
pression was the principle drug-related toxicity, with a frequency
of grade 3/4 neutropenia of 50% and grade 3/4 thrombocytopenia
of 15% (Hanauske et al, 2001). Less than 10% of patients
experienced gastrointestinal toxicities such as diarrhoea or
mucositis. Although the prevalence of gastrointestinal toxicities
and severe hematologic toxicities was low, these toxicities were
associated with a high risk of mortality.
Infrequent severe myelosuppression with gastrointestinal toxi-
city has been observed not only for pemetrexed, but for the class of
antifolates, including the DHFR inhibitor methotrexate (Morgan
et al, 1990), the TS inhibitor raltitrexed (Maughan et al, 1999), and
the GARFT inhibitor lometrexol (Alati et al, 1996; Mendelsohn
et al, 1996). Clinical experience and nonclinical studies with
methotrexate and lometrexol indicated that severe toxicity may be
associated with nutritional folate status (Morgan et al, 1990; Alati
et al, 1996; Mendelsohn et al, 1996). In fact, in the study of
lometrexol, a significant effect of folate supplementation on
toxicity was observed (Laohavinij et al, 1996). Based on these
experiences, Niyikiza et al (2002a) investigated relationships
between toxicity and baseline patient characteristics for early
pemetrexed studies. They found total plasma homocysteine and
methylmalonic acid levels to predict severe neutropenia and
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sthrombocytopenia, with or without grade 3/4 diarrhoea, mucositis,
or infection. Homocysteine and methylmalonic acid are
known as indicators of folate and vitamin B12 deficiencies
(Rosenberg and Fenton, 1989; Savage et al, 1994). Thus, it was
hypothesized that a patient’s risk for severe toxicity could be
reduced by decreasing the levels of homocysteine and methylma-
lonic acid with folate and vitamin B12 supplementation (FA/VB12)
(Niyikiza et al, 2002a).
FA/VB12 is now required for all patients participating in
pemetrexed studies. Using this strategy, the pivotal phase III
studies for MPM and NSCLC were successfully conducted with
amelioration of severe drug-related toxicity (Niyikiza et al, 2002b;
Vogelzang et al, 2003; Hanna et al, 2004).
One may expect that pemetrexed administration with supple-
mentation would be more tolerable for patients and permit
significant dose escalation above the current RD of 500mgm
 2.
Therefore, we conducted a phase I study to determine the MTD of
pemetrexed with FA/VB12 for Japanese patients with solid tumours
and to identify the RD for subsequent Japanese phase II studies.
Our secondary objectives were to investigate the safety, antitumour
effect, and pharmacokinetics of pemetrexed with supplementation
in Japanese patients. A similar phase I study has been conducted
outside Japan, but only preliminary data are available at this time
(Hammond et al, 2003).
PATIENTS AND METHODS
Patient selection
Eligible patients had histologic or cytologic diagnosis of solid
cancer that was incurable by standard treatments. Patients also
must have been between 20 and 75 years of age, have an Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2,
and have an estimated life expectancy of at least 3 months.
Adequate organ function was required, which included bone
marrow reserve (white blood cell count 4.0–12.0 10
3mm
 3,
platelets X100 10
3mm
 3, haemoglobin X9.0gdl
 1, and abso-
lute granulocyte count X2.0 10
3mm
 3), hepatic function
(bilirubin p1.5 upper limit of normal, aspartate/alanine transa-
minase (AST/ALT) p2.5 upper limit of normal, and serum
albumin X2.5gdl
 1), renal function (serum creatinine pupper
limit of normal and Cockcroft and Gault creatinine clearance
X60mlmin
 1), and lung function (PaO2 X60torr).
Prior chemotherapy or hormone therapy was allowed if it was
carried out X14 days before study entry (X35 days for
nitrosourea or mitomycin-C). Previous radiotherapy was also
allowed, but only if p25% of marrow was irradiated and if it was
completed X21 days before study entry. Pretreated patients must
have recovered from all toxicities before study entry. Prior surgery
was allowed if patients recovered from the effect of the operation.
Patients were excluded from this study for active infection,
symptomatic brain metastasis, interstitial pneumonitis, or pul-
monary fibrosis diagnosed by chest X-ray, serious concomitant
systemic disorders incompatible with the study, clinically sig-
nificant effusions, or the inability to discontinue aspirin and other
nonsteroidal anti-inflammatory agents during the study.
This study was conducted in compliance with the guidelines of
good clinical practice and the Declaration of Helsinki Principles,
and it was approved by the local institutional review boards. All
patients gave written informed consent before study entry.
Treatment
Pemetrexed was administered as a 10-min infusion on day 1 of a
21-day cycle. Patients remained on study unless they were
discontinued because of disease progression, unacceptable adverse
events, inadvertent enrollment, use of excluded concomitant
therapy, cycle delay 442 days, or patient refusal.
Patients were instructed to take a daily 1g multivitamin with
500mg of folate beginning 1 week before day 1 of cycle 1 until study
discontinuation. Vitamin B12 (1000mg) was intramuscularly
injected, starting 1 week before day 1 of cycle 1 and repeated
every 9 weeks until study discontinuation.
Patients enrolled in pemetrexed clinical studies have received
dexamethasone prophylactically to avoid pemetrexed-induced
rash. As this was the first study of pemetrexed in Japanese
patients and the incidence of the drug-induced rash in Japanese
patients was unknown, the steroid was not to be administered
prophylactically.
Dose escalation
In this study, 10 dose levels of pemetrexed, 300, 500, 600, 700, 800,
900, 1000, 1200, 1450, and 1750mgm
 2, were to be examined with
a starting dose of 300mgm
 2. At dose levels from 300 to
1000mgm
 2, three patients were to be treated initially. If no
dose-limiting toxicities (DLTs) occurred during cycle 1, escalation
proceeded to the next dose level. If 1 DLT occurred, three patients
were added. If no additional DLTs were observed, escalation
proceeded to the next dose level. At dose levels from 1200 to
1750mgm
 2, six patients were to be treated at once. If two or more
patients had DLTs at any dose level, dose escalation stopped, and
this dose level was considered the MTD. The RD was then
established by discussion with principal investigators, and the
Efficacy and Safety Evaluation Committee.
A DLT was defined as the occurrence of one of the following
toxicities during cycle 1: any grade 3/4 nonhematologic toxicity
(except grade 3 nausea/vomiting and AST, ALT, or alkaline
phosphatase elevation o10 upper limit of normal that returns to
grade 0–1 by the beginning of cycle 2), grade 3/4 febrile
neutropenia (o1000mm
 3 with X38.01C), grade 4 leucopenia
(o1000mm
 3) or neutropenia (o500mm
 3) lasting X4 days,
thrombocytopenia (o20000mm
 3), or thrombocytopenia
(X20000mm
 3) requiring platelet transfusion. A failure to start
the second cycle by day 42 owing to toxicity was also considered a
DLT. All toxicities were assessed according to National Cancer
Institute-Common Toxicity Criteria (NCI-CTC) version 2.
Treatment assessments
Tumour response was assessed by the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria. Evaluable patients
were subjected to CT or MRI measurement to determine the size of
tumours at anytime at the discretion of investigators.
Pharmacokinetic analysis
Blood and urine were collected from each patient over a period of
72h following administration in cycle 1. Blood samples were taken
just before administration, at the end of infusion, and approxi-
mately 5, 15, 30min and 1, 2, 4, 6, 8, 24, 48 and 72h after the start
of infusion. Urine was collected over the following time intervals:
0–4, 4–8, 8–12, 12–24, 24–36, 36–48, 48–60, and 60–72h.
Plasma and urine samples were analysed for pemetrexed at Taylor
Technology Inc., Princeton, NJ, USA. Plasma samples were
analysed using a validated liquid chromatography/electrospray
ionisation-tandem mass spectrometry method that generated a
linear response over the concentration ranges of 10–2000ng/ml
and 1000–200000ng/ml (Latz et al, 2006). Urine samples were
analysed using a similar analytical technique (Chaudhary et al,
1999).
Pharmacokinetics were evaluated using noncompartmental
methods (WinNonlin Professional Version 3.1; Pharsight Corpora-
tion, Cary NC, USA). Pharmacokinetic parameters determined
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sbased on plasma concentration vs time data were maximum
plasma concentration (Cmax), elimination half-life (t1/2), area under
the plasma concentration vs time curve (AUC) from time 0 to
infinity (AUC0-N), volume of distribution at steady-state (Vss) and
plasma clearance (CLp) (Rowland and Tozer, 1995). The fraction of
drug excreted unchanged in urine (Fe) was calculated by dividing
the cumulative amount of pemetrexed excreted unchanged in urine
within 72h (Ae0–72) by the administered dose (Rowland and
Tozer, 1995).
RESULTS
Patient disposition and characteristics
From October 2001 to September 2004, a total of 35 Japanese
patients were enrolled and 31 were treated at four centres in Japan.
Four patients were not treated owing to protocol criteria not met
(n¼3) and investigator decision (n¼1). The majority of patients
were male (65%), had an ECOG performance status of 1 (84%),
were diagnosed with NSCLC (61%), and received prior chemo-
therapy (94%) (Table 1).
Dose escalation and dose-limiting toxicities
Three or six patients were enrolled at each dose level from 300 to
1200mgm
 2, except the 900mgm
 2 dose level (Table 2). At this
dose level, one additional patient was enrolled because a patient
was excluded from the DLT analysis. Before the dose initiation,
this patient had grade 3 fasting hyperglycemia that was aggravated
after the start of dosing. Therefore, this patient was rated as
inappropriate for evaluation.
The first DLT was observed at the 700mgm
 2 dose level. This
66-year-old woman with NSCLC experienced grade 3 ALT
elevation. After an additional three patients were enrolled, no
other DLTs were observed.
The next DLTs were observed at the 1200mgm
 2 dose level,
which enrolled six patients at once. One patient, a 72-year-old
woman with MPM, had grade 3 infection at day 6 of cycle 1.
Neutropenia was not simultaneously observed in this cycle. After
12 days, the event was resolved with antibiotics. This patient
continued in study with dose reduction to 1000mgm
 2. The other
patient, a 68-year-old man with NSCLC, had grade 2 rash at day 5
of cycle 1. The severity of the event reached grade 3 at day 7. After
9 days from the occurrence, rash was resolved with dexamethasone
and H1-antihistamine. This patient continued in study without
dose reduction. As two DLTs were observed, the 1200mgm
 2 dose
level was considered as the MTD. The RD for subsequent phase II
studies was then evaluated to be pemetrexed 1000mgm
 2. Both
events were considered as drug-related events by investigators.
Safety
The safety evaluation was completed from data obtained from
cycle 1–6 for all dose levels except 1200mgm
 2 (cycle 1–3). These
data were collected and analysed to evaluate safety when the MTD
and RD were determined. The major toxicities observed in 450%
of patients during all cycles evaluated for this report included rash,
nausea, anorexia, fatigue, ALT elevation, AST elevation, lactate
dehydrogenase elevation, leucopenia, neutropenia, lymphopenia,
hematocrit decreased, haemoglobin decreased and erythropenia
(Table 3). The most commonly reported grade 3/4 toxicity was
neutropenia: nine patients (29%) had grade 3 neutropenia, and one
patient (3%) had grade 4 neutropenia. Other grade 3/4 hematologic
toxicities were grade 3 leucopenia in four patients (13%), grade 4
leucopenia in one patient (3%), grade 3 lymphopenia in four
patients (13%), and grade 3 haemoglobin decreased in two patients
(6%). The most commonly reported grade 3 nonhematologic
toxicity was ALT elevation (four patients (13%)). Other grade 3
toxicities included AST elevation in one patient (3%), anorexia in
one patient (3%), infection in one patient (3%), malaise in one
patient (3%), and rash in one patient (3%) were observed. No
grade 4 nonhematologic toxicities were reported.
The only serious adverse event was observed at the 900mgm
 2
level. This 71-year-old man with NSCLC experienced grade 1
pyrexia at day 18 of cycle 3 and was hospitalized; however, the
event was resolved the next day. The investigator did not consider
it as a drug-related event. One patient at 900mgm
 2 level
discontinued treatment owing to adverse events (neutropenia,
anorexia, and pyrexia). No deaths were observed during the study
period or for 31 days after the last dose.
At the 900mgm
 2 and higher dose levels, all patients had either
grade 1/2 or grade 3/4 rash. At cycle 1, 25 patients experienced
rash. Of these, 20 patients received corticosteroid. At or after cycle
2, corticosteroid treatment was given only for nine rash events,
whereas rash events were observed in 20 cycles in cumulative total
among patients. In addition, the severity of rash quickly improved
or disappeared after administration of corticosteroid. Although the
protocol allowed corticosteroid use for prevention of rash from
cycle 2, only seven patients actually received the preventive
treatment. Among those who did not receive the prophylactic
Table 1 Baseline patient characteristics
Parameter N¼31
Sex, n (%)
Male 20 (65)
Female 11 (35)
Age, years
Median (range) 59 (31–74)
Mean (s.d.) 57 (11)
ECOG performance status, n (%)
0 4 (13)
1 26 (84)
2 1 (3)
Diagnosis, n (%)
Non-small cell lung cancer 19 (61)
Malignant pleural mesothelioma 7 (23)
Thymoma 2 (7)
Alveolar soft part sarcoma 1 (3)
Rectal cancer 1 (3)
Unknown primary cancer 1 (3)
Prior therapy, n (%)
Surgery 14 (45)
Radiation 9 (29)
Chemotherapy 29 (94)
ECOG¼Eastern Cooperative Oncology Group; s.d.¼standard deviation.
Table 2 Dose escalation and DLTs
Dose (mgm
 2) Number of patients DLTs (n)
300 3 None
500 3 None
600 3 None
700 6 G3 ALT elevation (1)
800 3 None
900 4
a None
1000 3 None
1200 6 G3 infection (1); G3 rash (1)
ALT¼alanine transaminase; DLT¼dose-limiting toxicity; G3¼grade 3.
aOne
patient was excluded for DLT analysis because of grade 3 hyperglycemia at the
beginning of the study.
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scorticosteroid, the incidence of a rash observed at, or after, cycle 2
was about one-third of the incidence observed in cycle 1.
Pharmacokinetic analysis
Mean dose-normalised pemetrexed plasma concentration vs time
profiles following single doses of 300–1200mgm
 2 pemetrexed
are provided in Figure 1. This body surface area (BSA)-normalized
dose range represents absolute doses of 414–2018mg in Japanese
patients with a mean BSA of 1.64m
2 (range, 1.36–1.97m
2).
Pharmacokinetic parameters for each dose group are sum-
marised in Table 4. Lack of a monotonic trend in CLp and Vss
between cohorts indicated that pemetrexed pharmacokinetics are
consistent across dose groups. Consistency of pemetrexed
pharmacokinetics across dose groups is also illustrated by the
lack of systematic pattern across dose groups in the dose-
normalised plasma concentration vs time profiles (Figure 1). The
overall mean t1/2 is approximately 2.74h and was essentially
similar across all dose groups (range, 2.28–3.62h).
In this study, pemetrexed was primarily excreted unchanged in
urine, which is consistent with its known elimination pathway (i.e.,
renal excretion). The Fe averaged 0.752 (range, 0.645–0.827). Mean
Fe values were consistent across dosing cohorts.
Tumour response
In this study, 23 of the 31 patients were evaluable for response by
RECIST criteria (Table 5). Partial responses (PRs) were observed
in four patients with NSCLC (one patient each at 500, 700, 800, and
1200mgm
 2) and one patient with thymoma at 500mgm
 2.I n
addition, one patient with NSCLC at 500mgm
 2 had a PR by the
World Health Organization criteria, but was not evaluable via
RECIST.
DISCUSSION
This is the first phase I study of pemetrexed in Japanese patients.
The MTD for pemetrexed administered with FA/VB12 was
1200mgm
 2 and determined the RD for subsequent phase II
studies was 1000mgm
 2.
In contrast with the previously determined MTD (600mgm
 2)
without vitamin supplementation (Rinaldi et al, 1999), our MTD
Table 3 Incidence of clinically relevant toxicities
Dose (mgm
 2)( n)
Grade
300 (3) 500 (3) 600 (3) 700 (6) 800 (3) 900 (4) 1000 (3) 1200 (6)
Toxicity 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Hematologic
Erythropenia 1010304020202 0 5 0
Hematocrit decreased 1010304030202 0 5 0
Haemoglobin decreased 2020203020112 0 4 1
Leucopenia 1030213111111 0 5 1
Lymphopenia 0021013010113 0 4 1
Neutropenia 1012123202112 0 2 1
Thrombocytopenia 0020102020201 0 2 0
Nonhematologic
ALT elevation 0020202330111 0 5 0
AST elevation 0030204130302 0 5 0
Blood bilirubin increased 0010002000000 0 1 0
LDH elevation 0030305030201 0 4 0
Alopecia 0000202010200 0 0 0
Anorexia 0010305030013 0 4 0
Constipation 1010001000002 0 1 0
Diarrhoea 0020101010101 0 2 0
Fatigue 1020202030102 0 3 0
Infection 0000002000000 0 0 1
Nausea 2030305030202 0 5 0
Malaise 0000100100000 0 0 0
Pruritus 0000202010001 0 2 0
Rash 3020305020403 0 5 1
Vomiting 2030203010101 0 0 0
ALT¼alanine transaminase; AST¼aspartate transaminase; LDH¼lactate dehydrogenase.
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Cycle 1
Figure 1 Mean dose-normalised pemetrexed plasma concentration–
time profiles following single-dose administration in Japanese patients.
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sincreased by a factor of 2 whereas maintaining a tolerable safety
profile. Niyikiza et al (2002a,b) conducted a multivariate analysis
on 246 patients in phase II pemetrexed studies without vitamin
supplementation, and the incidence of grade 4 neutropenia was
32% and grade 4 thrombocytopenia was 8% . Also 6% of patients
had grade 3/4 diarrhoea, 5% had grade 3/4 mucositis, and a 5%
incidence of drug-related death occurred. In contrast, our study
had grade 4 neutropenia of only 3% (one patient) and no grade 4
thrombocytopenia. In addition, no grade 3/4 diarrhoea or
mucositis, and no drug-related deaths were observed.
In the pivotal phase III study of NSCLC patients, those who
received pemetrexed (500mgm
 2) plus vitamin supplementation
had a lower incidence of severe toxicities compared to those who
received docetaxel (75mgm
 2), including grade 3/4 neutropenia
(5.3 vs 40.2%) and grade 3/4 diarrhoea (0.4 vs 2.5%) (Hanna et al,
2004).
Dose-dependency for toxicity of pemetrexed plus supplementa-
tion was further investigated to understand the effect of
supplementation on safety. The patients in this study were divided
into three groups by doses: low dose (300–600mgm
 2 (n¼9)),
middle dose (700–900mgm
 2 (n¼13)), and high dose (1000 and
1200mgm
 2 (n¼9)). Grade 1/2 toxicity such as erythropenia,
lymphopenia, hematocrit decreased, ALT and AST elevation, and
anorexia increased dose dependently from approximately 20–50%
to approximately 75%. However, there was no obvious correlation
between grade 3/4 toxicity and dose group. Therefore, high dose
levels of pemetrexed with FA/VB12 is expected to be tolerable
enough for patients.
In this study, severe rash was rarely observed even without the
prophylactic corticosteroid. Although this result suggests that the
steroid premedication for prevention of severe rash is no longer
necessary for patients with pemetrexed treatment if the FA/VB12 is
concomitantly conducted, it would be too early to conclude it as
the data of patients untreated with the premedication are limited at
this moment.
The pharmacokinetic results in our study were consistent with a
phase I study of pemetrexed without vitamin supplementation in
western patients by Rinaldi et al (1999) In that study, pemetrexed
t1/2 was 3.1h; and CL was 85ml/min (Rinaldi et al, 1999 and
unpublished results). In our study, the t1/2 of pemetrexed was
about 2.7h; and CL was 81.9ml/min. Additionally, the Fe of
pemetrexed was similar for Japanese patients (75% in our study)
and western patients (78% in the Rinaldi study (Rinaldi et al,
1999)). These results indicate that pharmacokinetics of pemetrexed
in Japanese patients are similar to those in western patients.
Although our study is the first phase I study to evaluate
pemetrexed with FA/VB12 in Japanese patients, a similar phase I
study has been conducted in western patients. In the preliminary
results of that study, heavily pretreated patients had a MTD of
925mgm
 2, and lightly pretreated patients had a MTD of
1050mgm
 2 (Hammond et al, 2003). The comparison of these
two studies suggests that the improved tolerability experienced by
Japanese patients when pemetrexed is administered with FA/VB12
is not attributable to ethnic differences; rather, it is attributable to
the vitamin supplementation.
In our phase I study, four NSCLC patients and one thymoma
patient had PRs. Except for one, all of the patients with PR had X3
prior chemotherapy regimens. The NSCLC patients with PRs
received doses of pemetrexed higher than 500mgm
 2, which is the
approved dose for NSCLC treatment in a number of countries.
Therefore, subsequent phase II studies using our RD of
1000mgm
 2 with vitamin supplementation could show more
prominent antitumour activity for cancer patients. To examine this
hypothesis, a Japanese phase II study is being conducted,
examining pemetrexed 500 or 1000mgm
 2 every 3 weeks with
full supplementation for patients with locally advanced or
metastatic NSCLC. Clinical trials for other tumours, including
MPM, are also ongoing. For the prophylactic corticosteroid, as
severe rash was not frequently observed in this study, the steroid is
not to be administered prophylactically in both currently on-going
studies.
In conclusion, pemetrexed with FA/VB12 resulted in a tolerable
toxicity profile. The MTD was 1200mgm
 2. The RD was
1000mgm
 2.
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Table 4 Summary of pemetrexed pharmacokinetic parameters by dosing cohort arithmetic mean (CV%)
Dose (mgm
 2)( n)
Parameter 300 (3) 500 (3) 600 (3) 700 (6) 800 (3) 900 (4) 1000 (3) 1200 (6)
Dose (mg) 459 (12.4%) 783 (7.56%) 919 (8.28%) 1180 (8.06%) 1280 (16.5%) 1550 (5.47%) 1820 (7.04%) 1910 (6.71%)
Cmax,( mgml
 1) 58.2 (7.15%) 115 (19.1%) 178 (15.7%) 172 (9.30%) 240 (14.5%) 217 (7.05%) 269 (17.8%) 212 (13.2%)
AUC0-N, (mghml
 1) 70.1 (7.04%) 158 (21.6%) 290 (12.5%) 250 (23.5%) 361 (17.0%) 388 (19.6%) 382 (6.55%) 337 (24.6%)
CLp (mlmin
 1) 109 (5.89%) 86.5 (32.5%) 53.0 (3.95%) 83.4 (27.7%) 61.4 (35.2%) 68.5 (20.0%) 79.3 (2.57%) 99.7 (24.7%)
Vss (l) 13.5 (22.2%) 12.1 (20.1%) 11.5 (25.5%) 11.7 (20.0%) 10.6 (33.6%) 13.9 (31.7%) 14.4 (7.40%) 14.8 (9.41%)
t1/2 (h) 2.28 (25.2%) 2.62 (3.29%) 3.62 (28.7%) 2.51 (3.91%) 2.93 (14.6%) 3.02 (17.8%) 2.67 (1.90%) 2.55 (10.9%)
Fe 0.659 (8.78%) 0.645 (8.34%) 0.788 (3.76%) 0.807 (10.1%) 0.705 (34.9%) 0.797
a (5.11%) 0.648
a (12.5%) 0.827
a (7.58%)
CV%¼coefficient of variation expressed as a percentage; Cmax¼maximum observed drug concentration; AUC0-N¼area under the concentration versus time curve from zero
to infinity; CL¼total body clearance of drug after intravenous administration; Vss¼volume of distribution at steady state; t1/2¼half-life associated with the terminal rate constant;
Fe¼fraction of dose eliminated unchanged in urine.
aThe numbers of patients in 900, 1000, and 1200mgm
 2 were three, two, and five, respectively, owing to incompletion of
urine collections for patients 209, 210, and 306.
Table 5 Antitumour activity by dose (RECIST)
Evaluable (n¼23)
Dose (mgm
 2) Number of patients CR PR
a s.d. PD NE
300 3 0 0 2 0 1
500 3 0 2 0 0 0
600 3 0 0 1 0 0
700 6 0 1 3 1 0
800 3 0 1 0 1 1
900 4 0 0 2 0 1
1000 3 0 0 1 1 0
1200 6 0 1 2 1 0
Total 31 0 5 11 4 3
NSCLC¼non-small cell lung cancer; CR¼complete response; NE¼not evaluated;
PD¼progressive disease; PR¼partial response; s.d.¼stable disease.
aIn addition,
one NSCLC patient at 500mgm
 2 had PR via WHO criteria.
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